Renal Transplantation Clinical Trial
Official title:
The Effect of Rimonabant Treatment on Cardiovascular Risk Factors in Renal Transplant Recipients -- Pilot Safety Study
The major cause of premature death in renal transplant recipients is cardio-vascular disease. In addition, obesity is becoming a major problem in this patient population. Rimonabant does not only seem to have weight reducing properties but also weight reduction independent effects on insulin sensitivity and endothelial function, two important cardio-vascular risk factors. Rimonabant therefore is an interesting drug for the treatment of transplanted patients. Present data also indicate that rimonabant does not interact with essential immunosuppressive drugs (CsA and Tac) indicating that it most probably is safe to administer to this patient population. However this needs to be investigated in a proper manner.
Renal transplant recipients are treated with life-long immunosuppressive therapy in order to prevent acute rejection episodes. The calcineurin inhibitors (CsA and Tac) are the back-bones in the immunosuppressive treatment and they have a very narrow therapeutic index. It is therefore essential to assure that new drug to be used in transplanted patients do not interact with CsA and Tac. Even though rimonabant is metabolized via the same enzyme as CsA and Tac (CYP3A4) previous in vitro and in vivo studies with relevant probe drugs in healthy volunteers do not indicate the presence of any relevant pharmacokinetic interaction. However, to be absolutely sure that it is safe to administer rimonabant in transplanted patients a 12-hour pharmacokinetic interaction investigation is included for 16 patients in the present pilot study (8 patients on CsA and 8 patients on Tac). ;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
| Active, not recruiting |
NCT02444429 -
3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation
|
Phase 3 | |
| Completed |
NCT02238418 -
Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.
|
Phase 4 | |
| Completed |
NCT01729494 -
Belatacept Early Steroid Withdrawal Trial
|
Phase 4 | |
| Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 | |
| Terminated |
NCT01276834 -
Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation
|
Phase 4 | |
| Completed |
NCT02843295 -
Catalytic Antibodies to Predict Uninvasively Late Transplant Failure
|
N/A | |
| Completed |
NCT00842699 -
Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
|
N/A | |
| Completed |
NCT00776750 -
Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients
|
Phase 4 | |
| Completed |
NCT00189735 -
A Study to Evaluate FK778 in Kidney Transplant Patients
|
Phase 2 | |
| Recruiting |
NCT04052867 -
Intravenous Lignocaine Infusion in Laparoscopic Donor Nephrectomy
|
N/A | |
| Recruiting |
NCT03114826 -
Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients
|
N/A | |
| Completed |
NCT02587052 -
A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac
|
||
| Completed |
NCT02020642 -
Effect of Renal Transplantation on Obstructive Sleep Apnea in End Stage Renal Disease Patients (SASinTx)
|
N/A | |
| Completed |
NCT01435291 -
AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation
|
Phase 4 | |
| Recruiting |
NCT01001065 -
Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis
|
N/A | |
| Completed |
NCT00978965 -
Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodrugs
|
||
| Recruiting |
NCT00903188 -
Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation
|
Phase 4 | |
| Completed |
NCT00419575 -
Renal Transplantation With Immune Monitoring
|
N/A | |
| Completed |
NCT00425308 -
Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.
|
Phase 3 |